BHVN250516C12500
- 9.90
- -0.40-3.88%
Biohaven Newsroom
Baird Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $57
Biohaven Analyst Ratings
Baird Maintains Outperform on Biohaven, Lowers Price Target to $57
William Blair Initiates Biohaven(BHVN.US) With Buy Rating
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $61
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $75
Biohaven Analyst Ratings
Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $63
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $63
Piper Sandler Initiates Biohaven(BHVN.US) With Buy Rating, Announces Target Price $76
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $63
Optimistic Buy Rating for Biohaven Ltd. Amid Promising Drug Developments and Strategic Pipeline Advancements
Bernstein Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $57
Biohaven Price Target Cut to $68.00/Share From $72.00 by JP Morgan
Biohaven Is Maintained at Overweight by JP Morgan
Leerink Partners Maintains Biohaven(BHVN.US) With Buy Rating, Announces Target Price $60
Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), 4D Molecular Therapeutics (FDMT) and Biohaven Ltd. (BHVN)
H.C. Wainwright Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $54
Biohaven Analyst Ratings
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $75